和蛋白质标签用于治疗剂的半衰期延长:一篇评论文章
Sorour Aboutalebi1, Fatemeh Najafi1, Negin Yazdizadeh1
1Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Hezar Jarib Ave., Isfahan, Iran.
The protein journal
|December 1, 2025
概括
生物药物通过半衰期延长标签获得更长的循环时间. 这些和蛋白质标签提高了药物的稳定性,减少了清除,提高了治疗效果.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
背景情况:
- 生物药物面临着由于快速降解和清除而在体内半衰期短的挑战.
- 提高蛋白质和治疗药物的稳定性和循环时间对于有效治疗至关重要.
- 半衰期延长标签提供了一个有希望的战略,以克服药物开发中的这些局限性.
研究的目的:
- 审查延长生物药物的半衰期的和蛋白质标签.
- 讨论这些标签改善药理动力学特征的机制.
- 突出目前FDA批准的产品和使用半衰期延长技术的临床候选者.
主要方法:
- 科学出版物和临床试验数据的文献综述.
- 对各种半衰期延长标签的分析,包括HSA,ABD,DARPINS,XTEN,CTP和ELP.
- 专注于白蛋白结合域及其在延长药物半衰期中的应用.
主要成果:
- 几种和蛋白质标签有效地增加了生物药物的循环半衰期.
- 包括AlbudAb在内的蛋白结合域通过利用人血清蛋白的高丰度和稳定性,显示出显著的潜力.
- 一系列标记生物药物正在临床开发中取得进展,这表明这种方法的可行性.
结论:
- 半衰期延长标签是提高生物药物的治疗疗效的重要策略.
- 专结合策略是延长药物循环的特别有效方法.
- 这些标签的持续开发和应用对未来的生物疗法具有重大前景.
相关概念视频
Tagging and Fusion Proteins
6.4K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.4K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
144
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
144
Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165


